Search Results - "Eichau Madueño, S."

Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center by Rodríguez de Vera Gómez, P., García-González, J. J., Ravé-García, R., López Ruiz, R., Torres-Cuadro, A., Eichau-Madueño, S., García-García, C., Martín-Hernández, T.

“…Objectives Graves’ disease induced by Alemtuzumab (GD-IA) is one of the most frequently observed adverse events in patients with multiple sclerosis (MS)…”
Get full text

Usefulness of optic nerve ultrasound to predict clinical progression in multiple sclerosis by Pérez Sánchez, S, Eichau Madueño, S, Rus Hidalgo, M, Domínguez Mayoral, A M, Vilches-Arenas, A, Navarro Mascarell, G, Izquierdo, G

“…INTRODUCTIONProgressive neuronal and axonal loss are considered the main causes of disability in patients with multiple sclerosis (MS). The disease frequently…”
Get full text

Usefulness of optic nerve ultrasound to predict clinical progression in multiple sclerosis by Pérez Sánchez, S., Eichau Madueño, S., Rus Hidalgo, M., Domínguez Mayoral, A.M., Vilches-Arenas, A., Navarro Mascarell, G., Izquierdo, G.

“…Progressive neuronal and axonal loss are considered the main causes of disability in patients with multiple sclerosis (MS). The disease frequently involves the…”
Get full text

Consensus statement on the use of alemtuzumab in daily clinical practice in Spain by Meca-Lallana, J E, Fernández-Prada, M, García Vázquez, E, Moreno Guillén, S, Otero Romero, S, Rus Hidalgo, M, Villar Guimerans, L M, Eichau Madueño, S, Fernández Fernández, Ó, Izquierdo Ayuso, G, Álvarez Cermeño, J C, Arnal García, C, Arroyo González, R, Brieva Ruiz, L, Calles Hernández, C, García Merino, A, González Platas, M, Hernández Pérez, M Á, Moral Torres, E, Olascoaga Urtaza, J, Oliva-Nacarino, P, Oreja-Guevara, C, Ortiz Castillo, R, Oterino, A, Prieto González, J M, Ramió-Torrentá, L, Rodríguez-Antigüedad, A, Saiz, A, Tintoré, M, Montalbán Gairin, X

“…INTRODUCTIONAlemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of…”
Get full text

Consensus statement on the use of alemtuzumab in daily clinical practice in Spain by Meca-Lallana, J.E., Fernández-Prada, M., García Vázquez, E., Moreno Guillén, S., Otero Romero, S., Rus Hidalgo, M., Villar Guimerans, L.M., Eichau Madueño, S., Fernández Fernández, Ó., Izquierdo Ayuso, G., Álvarez Cermeño, J.C., Arnal García, C., Arroyo González, R., Brieva Ruiz, L., Calles Hernández, C., García Merino, A., González Plata, M., Hernández Pérez, M.Á., Moral Torres, E., Olascoaga Urtaza, J., Oliva-Nacarino, P., Oreja-Guevara, C., Ortiz Castillo, R., Oterino, A., Prieto González, J.M., Ramió-Torrentá, L., Rodríguez-Antigüedad, A., Saiz, A., Tintoré, M., Montalbán Gairin, X.

“…Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple…”
Get full text

Utilidad de la ecografía de nervio óptico como predictor de progresión en esclerosis múltiple by Pérez Sánchez, S., Eichau Madueño, S., Rus Hidalgo, M., Domínguez Mayoral, A.M., Vilches-Arenas, A., Navarro Mascarell, G., Izquierdo, G.

“…Introducción La pérdida neuronal/axonal progresiva se considera la causa más importante de discapacidad neurológica en la esclerosis múltiple (EM). El sistema…”
Get full text

Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España by Meca-Lallana, J.E., Fernández-Prada, M., García Vázquez, E., Moreno Guillén, S., Otero Romero, S., Rus Hidalgo, M., Villar Guimerans, L.M., Eichau Madueño, S., Fernández Fernández, Ó., Izquierdo Ayuso, G., Álvarez Cermeño, J.C., Arnal García, C., Arroyo González, R., Brieva Ruiz, L., Calles Hernández, C., García Merino, A., González Platas, M., Hernández Pérez, M.Á., Moral Torres, E., Olascoaga Urtaza, J., Oliva-Nacarino, P., Oreja-Guevara, C., Ortiz Castillo, R., Oterino, A., Prieto González, J.M., Ramió-Torrentá, L., Rodríguez-Antigüedad, A., Saiz, A., Tintoré, M., Montalbán Gairin, X.

“…Resumen: Introducción: Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europea de Medicamentos como tratamiento modificador de la enfermedad…”
Get full text

Vitíligo con fenómeno de Koebner en una paciente con esclerosis múltiple tratada con alemtuzumab by Eichau Madueño, Sara, López Ruiz, Rocío, Ruiz Peña, Juan Luis, Páramo Camino, Mª Dolores, Navarro Mascarell, Guillermo, Izquierdo Ayuso, Guillermo

Get full text

High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag by Roos, I., Leray, Emmanuelle, Casey, Romain, Horakova, D., Havrdova, E. Kubala, Izquierdo, G., Eichau Madueno, S., Patti, F., Edan, Gilles, Debouverie, Marc, Pelletier, Jean, Ozakbas, S., Amato, M. P., Clavelou, Pierre, Grammond, P., Boz, C., Ciron, Jonathan, Gerlach, O., Grand'Maison, F., Lechner-Scott, J., Malpas, C., Butzkueven, H., Vukusic, S., Kalincik, T.

Get full text